Q&A: Cancer Commons' Tenenbaum on Building a Patient-Centric System for Personalized Oncology | GenomeWeb

The already long and expensive process of bringing a drug from discovery to market is further challenged by the entrance of personalized medicine products, which don't neatly fit into industry's existing business models or the US Food and Drug Administration's regulatory pathways.

Genomically guided personalized medicine products have so far emerged most readily in oncology. But even drug and diagnostics companies developing genomic medicines in the cancer space have experienced setbacks due to regulatory and market challenges.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.